Literature DB >> 18640568

Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.

Gabriela Rondón1, Rima M Saliba, Issa Khouri, Sergio Giralt, Kawah Chan, Elias Jabbour, John McMannis, Richard Champlin, Elizabeth Shpall.   

Abstract

The long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has not been well described. To fill this knowledge gap we performed a retrospective analysis of patients with graft failure over a 10-year time period in a single institution. Cases were included for analysis if they had failed to achieve an absolute neutrophil count (ANC) of 500/microL or more by 28 days post-SCT or 42 days after cord blood transplantation (primary graft failure); had a decrease in their ANC to <500/mL for 3 consecutive days after having achieved neutrophil engraftment (secondary graft failure); or failed to have evidence of at least 5% or more donor cell engraftment (primary graft failure with autologous reconstitution). Among 1726 patients who underwent allografts from January 1, 1990, through December 31, 2000, we identified 68 patients with graft failure. The 1-, 2-, and 5-year overall survival (OS) for all patients was 31%, 24%, and 15%. A diagnosis of acute leukemia was a significant predictor for poor survival on multivariate analysis. We conclude that graft failure is an uncommon complication postallogeneic SCT, and is associated with poor outcomes. Collection of autologous stem cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals.

Entities:  

Mesh:

Year:  2008        PMID: 18640568      PMCID: PMC4548938          DOI: 10.1016/j.bbmt.2008.05.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

1.  Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation.

Authors:  P Guardiola; M Kuentz; F Garban; D Blaise; J Reiffers; M Attal; A Buzyn; B Lioure; P Bordigoni; N Fegueux; M L Tanguy; J P Vernant; E Gluckman; G Socié
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

Review 2.  Graft rejection and graft-versus-host disease in marrow transplantation.

Authors:  R Storb
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.

Authors:  J Nemunaitis; J W Singer; C D Buckner; D Durnam; C Epstein; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

4.  Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect.

Authors:  R Champlin; I Khouri; S Komblau; J Molidrem; S Giralt
Journal:  Oncology (Williston Park)       Date:  1999-05       Impact factor: 2.990

Review 5.  Marrow transplantation for aplastic anemia.

Authors:  R Storb; E D Thomas; C D Buckner; F R Appelbaum; R A Clift; H J Deeg; K Doney; J A Hansen; R L Prentice; J E Sanders
Journal:  Semin Hematol       Date:  1984-01       Impact factor: 3.851

6.  Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.

Authors:  Ray Y Hachem; Krystal Hicks; Auris Huen; Issam Raad
Journal:  Clin Infect Dis       Date:  2003-06-25       Impact factor: 9.079

7.  Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.

Authors:  Karen K Ballen; Pamela S Becker; Robert V B Emmons; Thomas J Fitzgerald; Chung C Hsieh; Qin Liu; Christine Heyes; Yeteive Clark; William Levy; Jean Francois Lambert; Frank Chiafari; Irma Szymanski; Sarah Rososhansky; Mark A Popovsky; F Marc Stewart; Peter J Quesenberry
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Frédéric Baron; Jennifer E Baker; Rainer Storb; Theodore A Gooley; Brenda M Sandmaier; Michael B Maris; David G Maloney; Shelly Heimfeld; Dmitrij Oparin; Eustacia Zellmer; Jerald P Radich; F Carl Grumet; Karl G Blume; Thomas R Chauncey; Marie-Térèse Little
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

9.  Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.

Authors:  Frank Heinzelmann; Peter J Lang; Hellmut Ottinger; Christoph Faul; Wolfgang Bethge; Rupert Handgretinger; Michael Bamberg; Claus Belka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

10.  Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation.

Authors:  M Remberger; O Ringdén; P Ljungman; H Hägglund; J Winiarski; B Lönnqvist; J Aschan
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

View more
  15 in total

1.  Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.

Authors:  Sebastian P Haen; Michael Schumm; Christoph Faul; Lothar Kanz; Wolfgang A Bethge; Wichard Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-14       Impact factor: 4.553

2.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

3.  Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Authors:  Sebastian P Haen; Vicky Eyb; Nora Mirza; Aline Naumann; Andreas Peter; Markus W Löffler; Christoph Faul; Wichard Vogel; Wolfgang A Bethge; Hans-Georg Rammensee; Lothar Kanz; Martin Heni
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-16       Impact factor: 4.553

4.  Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning.

Authors:  B Askaa; A Fischer-Nielsen; L Vindeløv; E K Haastrup; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2014-02-03       Impact factor: 5.483

5.  Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation.

Authors:  Masahiko Sumi; Ikuo Shimizu; Keijiro Sato; Toshimitsu Ueki; Daigo Akahane; Mayumi Ueno; Naoaki Ichikawa; Shinji Nakao; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2010-11-05       Impact factor: 2.490

6.  Second unrelated donor hematopoietic cell transplantation for primary graft failure.

Authors:  Jeffrey Schriber; Manza-A Agovi; Vincent Ho; Karen K Ballen; Andrea Bacigalupo; Hillard M Lazarus; Christopher N Bredeson; Vikas Gupta; Richard T Maziarz; Gregory A Hale; Mark R Litzow; Brent Logan; Martin Bornhauser; Roger H Giller; Luis Isola; David I Marks; J Douglas Rizzo; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-19       Impact factor: 5.742

7.  Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells.

Authors:  M Kwon; C Martínez-Laperche; P Balsalobre; D Serrano; J Anguita; J Gayoso; J L Díez-Martín; I Buño
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

8.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 9.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.

Authors:  Stefan O Ciurea; Kai Cao; Marcelo Fernandez-Vina; Piyanuch Kongtim; Monzr Al Malki; Ephraim Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Rupert Handgretinger; Denis-Claude Roy; Paul O'Donnell; Asad Bashey; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2018-01-15       Impact factor: 5.483

10.  Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

Authors:  Boglarka Gyurkocza; Thai M Cao; Rainer F Storb; Thoralf Lange; Wendy Leisenring; Georg N Franke; Mohamed Sorror; Richard Hoppe; David G Maloney; Robert S Negrin; Judith A Shizuru; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.